MK0476 Study in Adult Patients With Allergic Rhinitis (0476-378)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

945 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-02-29

Study Completion Date

2004-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The clinical study evaluates the efficacy and safety of MK0476 in adult patients with allergic rhinitis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

MK0476 Study in Adult Patients With Perennial Allergic Rhinitis (0476-397)(COMPLETED)

NCT00771160

Rhinitis, Allergic

COMPLETED PHASE3

An Approved Drug to Study a New Indication for Allergic Rhinitis (0476-327)

NCT00127647

Rhinitis, Allergic, Seasonal

COMPLETED PHASE3

An Approved Drug to Study a New Indication for Seasonal Allergic Rhinitis in Patients With Asthma (0476-269)

NCT00092885

Rhinitis, Allergic, Seasonal Asthma, Bronchial

COMPLETED PHASE3

Study of the Efficacy and Safety of MK-0476 in Japanese Pediatric Participants With Seasonal Allergic Rhinitis (MK-0476-519)

NCT01857063

Seasonal Allergic Rhinitis

COMPLETED PHASE3

Study of MK0476 (Montelukast Sodium) and Effects on Asthma and Nasal Symptoms Upon Exposure to Cats (0476-256)

NCT00092105

Asthma, Bronchial Rhinitis, Allergic, Perennial

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rhinitis Allergic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MK0476, montelukast sodium / Duration of Treatment: 2 Weeks

Intervention Type DRUG

Comparator: placebo / Duration of Treatment: 2 Weeks

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients with seasonal allergic rhinitis

Exclusion Criteria

* Patients who have nasal diseases (e.g., nasal polyp, septonasal arcuation, hypertrophic rhinitis), upper respiratory infection, sinusitis, infectious rhinitis, ocular infection and those disease severe enough to interfere with assessment of effectiveness
* Patients who have rhinitis medicamentosa, or nonallergic rhinitis (e.g., vasomotor rhinitis, eosinophilia rhinitis)
* Patient has a disease of the cardiovascular, hepatic, renal, hematologic systems, or other severe disease

Minimum Eligible Age

15 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No